Qualitative Evaluation of Fiducial Markers for Radiotherapy Imaging

Technology in Cancer Research and Treatment

Volumn 14, Issue 3, 2015, Pages 298-304

  Chan, Maria F ^a   Cohen, Gil’ad N ^a   Deasy, Joseph O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

fiducial markers; IGRT; radiotherapy; target motion

Indexed keywords

FIDUCIAL MARKER; UNCLASSIFIED DRUG; GOLD; POLYMER;

ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ELECTRONIC PORTAL IMAGING DEVICE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GOLD STANDARD; HUMAN; IMAGE ANALYSIS; RADIODIAGNOSIS; ULTRASOUND; ALGORITHM; ARTIFACT; CHEMISTRY; ECHOGRAPHY; FIDUCIAL MARKER; IMAGE GUIDED RADIOTHERAPY; IMAGE PROCESSING; IMAGING PHANTOM; MAGNETIC AND ELECTROMAGNETIC EQUIPMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; SOFTWARE; X-RAY COMPUTED TOMOGRAPHY;

ALGORITHMS; ARTIFACTS; CONE-BEAM COMPUTED TOMOGRAPHY; FIDUCIAL MARKERS; GOLD; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; PARTICLE ACCELERATORS; PHANTOMS, IMAGING; POLYMERS; RADIOTHERAPY, IMAGE-GUIDED; SOFTWARE; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84954521610     PISSN: 15330346     EISSN: 15330338     Source Type: Journal    
DOI: 10.1177/1533034614547447     Document Type: Article

References (25)

1. B.J.EricksonC.R.JackJr. Correlation of single photon emission CT with MR image data using fiduciary markers. AJNR Am J Neuroradiol. 1993;14(3):713–720.
2. P.AdjamianG.R.BarnesA.Hillebrand. Co-registration of magnetoencephalography with magnetic resonance imaging using bite-bar-based fiducials and surface-matching. Clin Neurophysiol. 2004;115(3):691–698.
3. D.C.SchiffnerA.R.GottschalkM.Lometti. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67(2):610–619.
4. I.GauthierJ.F.CarrierD.Beliveau-NadeauB.FortinD.Taussky. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment. Int J Radiat Oncol Biol Phys. 2009;74(4):1128–1133. doi:10.1016/j.ijrobp.2008.09.043
5. J.S.WelshC.BertaS.Borzillary. Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy. Technol Cancer Res Treat. 2004;3(4):359–364.
6. B.M.BarneyR.J.LeeD.HandrahanK.T.WelshJ.T.CookW.T.Sause. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT). Int J Radiat Oncol Biol Phys. 2011;80(1):301–305. doi:10.1016/j.ijrobp.2010.06.007
7. G.J.van der WielenT.F.MutangaL.Incrocci. Deformation of prostate and seminal vesicles relative to intraprostatic fiducial markers. Int J Radiat Oncol Biol Phys. 2008;72(5):1604–1611. e3. doi:10.1016/j.ijrobp.2008.07.023
8. K.R.BrittonY.TakaiM.MitsuyaK.NernotoY.OgawaS.Yarmada. Evaluation of inter- and intrafraction organ motion during intensity modulated radiation therapy (IMRT) for localized prostate cancer measured by a newly developed on-board image-guided system. Radiat Med. 2005;23(1):14–24.
9. J.H.KilloranH.M.KooyD.J.GladstoneF.J.WelteC.J.Beard. A numerical simulation of organ motion and daily setup uncertainties: implications for radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37(1):213–221.
10. E.HuangL.DongA.Chandra. Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(2):261–268.
11. D.SkarsgardP.CadmanA.El-Gayed. Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers. Radiat Oncol. 2010;5:52. doi:10.1186/1748-717X-5-52.
12. R.KhosaS.NangiaK.S.ChufalD.GhoshR.KaulL.Sharma. Daily online localization using implanted fiducial markers and its impact on planning target volume for carcinoma prostate. J Cancer Res Ther. 2010;6(2):172–178.
13. N.J.YueA.N.PatelB.G.HafftyS.Kim. Efficacy of fiducial marker-based image-guided radiation therapy in prostate tomotherapy and potential dose coverage improvement using a patient positioning optimization method. Pract Radiat Oncol. 2012;2(2):138–144.
14. N.KotharyS.DieterichJ.D.LouieD.T.ChangL.V.HofmannD.Y.Sze. Percutaneous implantation of fiducial markers for imaging-guided radiation therapy. Am J Roentgenol. 2009;192(4):1090–1096.
15. L.L.HandsfieldN.J.YueJ.ZhouT.ChenS.Goyal. Determination of optimal fiducial marker across image-guided radiation therapy (IGRT) modalities: visibility and artifact analysis of gold, carbon, and polymer fiducial markers. J Applied Clini Med Phys. 2012;13(5):3976.
16. D.HabermehlK.HenknerS.EckerO.JakelJ.DebusS.E.Combs. Evaluation of different fiducial marker for image-guided radiotherapy and particle therapy. J Radiat Research. 2013;54(suppl 1):i61–i68.
17. J.H.JonssonA.GarpebringM.G.KarlssonT.Nyholm. Internal fiducial markers and susceptibility effects in MRI-simulation and measurement of spatial accuracy. Int J Radiat Oncol Biol Phys. 2012;82(5):1612–1618.
18. M.HossainT.SchirmerT.RichardsonL.ChenM.K.BuyyounouskiC.M.Ma. Effect of gold marker seeds on magnetic resonance spectroscopy of the prostate. Int J Radiat Oncol Biol Phys. 2012;83(1):451–458.
19. Y.ChenJ.J.O’ConnellC.J.KoR.R.MayerA.BelardJ.E.McDonough. Fiducial markers in prostate for kV imaging: quantification of visibility and optimization of imaging conditions. Phys Med Biol. 2012;57(1):155–172.
20. M.ZhangS.KimT.ChenX.MoB.G.HafftyN.J.Yue. Dose perturbations of gold fiducial markers in the prostate cancer intensity modulated proton radiation therapy (IMPT). Int J Med Phys Clinic Eng Rad Oncol. 2012;1(1):8–13. doi:10.4236/ijmpcero.2012.11002.
21. J.Y.HuangW.D.NewhauserX.R.ZhuA.K.LeeR.J.Kudchadker. Investigation of dose perturbations and radiographic visibility of potential fiducials for proton radiation therapy of the prostate. Phys Med Biol. 2011;56(16):5287–5302.
22. J.CheungR.J.KudchadkerX.R.ZhuA.K.LeeW.D.Newhauser. Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer. Phys Med Biol. 2010;55(23):7135–7147. doi:10.1088/0031-9155/55/23/S13
23. H.J.HuismanJ.J.FuttererA.Welmers. Prostate cancer: precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers. Radiology. 2005;236(1):311–317.
24. M.DeLangenM.HoogemanG.VanderWielenH.DeBoerB.HeijimenP.Levendag. What is the ultimate fiducial marker?Radiother Oncol. 2007;84:S181–S182.
25. A.M.HenryJ.StratfordJ.Davies. An assessment of clinically optimal gold marker length and diameter for pelvis radiotherapy verification using an amorphous silicon flat panel electronic portal imaging device. Br J Radiol. 2005;78(932):737–741. doi:Dx.doi.org/10.1259/bjr/97956788.